腹膜假黏液瘤的诊断与治疗研究进展  

Research Progress in Diagnosis and Treatment of Pseudomyxoma Peritonei

作　　者：史冠军 夏奥 蔚莉菲[1] 马瑞卿[1] 许洪斌[2] SHI Guan-jun;XIA Ao;YU Li-fei;MA Rui-qing;XU Hong-bin(Aerospace Central Hospital,Beijing 100049,China)

机构地区：[1]航天中心医院,北京100049 [2]航天中心医院黏液瘤科,北京100049

出　　处：《肿瘤学杂志》2021年第12期1034-1040,共7页Journal of Chinese Oncology

基　　金：首都卫生发展科研专项基金(20200522-CHDRP-03)。

摘　　要：腹膜假黏液瘤是一种罕见的临床综合征,主要来源于阑尾黏液肿瘤,以腹腔内充满黏液或胶冻样腹水为特征。发病率每年约3/100万~4/100万。由于其进展缓慢,无特异性临床症状,容易导致误诊。超声、CT等影像学检查有助于诊断。目前细胞减灭术与腹腔热灌注化疗相结合的综合治疗策略已经成为腹膜假黏液瘤标准的治疗方法,然而术后高复发率仍是亟待解决的难题。肿瘤减灭程度是影响生存预后的重要因素,而全身化疗能否获益尚存在争议。Pseudomyxoma peritonei is a rare clinical syndrome with a incidence rate of 0.3/10;~0.4/10;,which mainly comes from appendix myxoma and is characterized by mucus or jelly-like ascites in the abdominal cavity. Because of its slow progress and no specific clinical symptoms, it is often misdiagnosed. Ultrasonography, CT and other imaging examinations are helpful for diagnosis. At present, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the standard therapeutic strategy for pseudomyxoma peritonei, but the high postoperative recurrence rate is still the problem to be solved urgently. The extent of tumor attenuation is an important factor affecting survival and prognosis, but whether systemic chemotherapy can benefit is still controversial.

关 键 词：腹膜假黏液瘤 肿瘤细胞减灭术 腹腔热灌注化疗 

分 类 号：R730.262[医药卫生—肿瘤]